ArticleCellular and molecular life sciences : CMLS2025
The E3 ubiquitin ligase MARCH9 alleviates pyroptosis by regulating NLPR3 ubiquitination following myocardial ischemia reperfusion.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Molecular mechanisms of NLRP3 inflammasome activation.Experimental & molecular medicine · 2026Review
- MARCH E3 Ligases: Understudied Regulators of Pulmonary Immune Function.Journal of respiratory biology and translational medicine · 2026Article
- NLRP3-mediated pyroptosis in cardiovascular disease: from molecular mechanisms to therapeutic targets.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
NLRP3, a member of the NOD-like receptor family, mediates pyroptosis via inflammasome activation, contributing significantly to myocardial ischemia-reperfusion (MI/R) injury. However, the molecular mechanisms remain unclear. This study aimed to elucidate the mechanisms underlying NLRP3 inflammasome activation and its role in pyroptotic myocyte death following MI/R injury, with a particular focus on the effects of MARCH9, an E3 ubiquitin ligase that encodes a RING finger domain. In our in vivo experiments, we established an MI/R injury model by ligating the anterior descending branch of the coronary artery in mice. Cardiac tissues were analyzed using various methods, including proteomic analysis, TTC and Evan's blue dual-dye staining, immunohistochemical staining (F4/80, CD11b and Ly6G), and immunofluorescent staining (GSDMD-N). Western blotting was also performed to assess the expression of key pyroptosis-related proteins, such as MARCH9, NLRP3, caspase-1, GSDMD-N, and AIM2. In vitro studies in H9C2 and HEK293 cell lines involved western blotting, co-immunoprecipitation, and immunofluorescent staining to examine protein interactions and functional domains. Our findings reveal that MARCH9 plays a key regulatory role in NLRP3 inflammasome activation and pyroptosis during MI/R injury. MARCH9 was identified as an E3 ubiquitin ligase that interacts with NLRP3, promoting its K48-linked polyubiquitination and subsequent proteasomal degradation. This process inhibits NLRP3 activation, thereby mitigating pyroptosis and reducing myocardial injury. In conclusion, MARCH9 suppresses pyroptosis by modulating NLRP3 ubiquitination in response to MI/R injury, highlighting its potential as a novel cardioprotective target for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.